Skip to main content
main-content

JAK inhibitor safety

Weighing up the data and understanding the risks

What you need to know

A number of JAK inhibitors are now approved for the treatment of rheumatic diseases in different settings, but questions remain about their long-term safety profiles and overall place in therapy.

Take a look below for in-depth discussion of the potential risks associated with JAK inhibitors and what these mean for rheumatologists, as well as news on the latest safety data and approvals for this class of drugs.

Feature article

JAK inhibitor safety: Distilling the evidence

Approval timeline

Peter Nash discusses the latest evidence on the association between JAK inhibitors and the risk for VTE, MACE, and malignancy.

‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

Safety snapshot: Upadacitinib in patients with psoriatic arthritis

Access our overview of the key safety data from the SELECT-PsA studies.

Regulatory updates

FDA requires boxed warning updates for JAK inhibitors

The US FDA has issued an updated safety communication announcing that boxed warnings on the labels for tofacitinib, baricitinib, and upadacitinib must be updated to include information on the risk for serious cardiovascular events, cancer, blood clots, and death.

EMA gives nod to upadacitinib for psoriatic arthritis, ankylosing spondylitis

The EMA’s Committee for Medicinal Products for Human Use has recommended that the indication for upadacitinib should be expanded to include psoriatic arthritis and ankylosing spondylitis.

Related news

02-09-2021 | JAK inhibitors | News

FDA requires boxed warning updates for JAK inhibitors

Click through for more information on this announcement

06-08-2021 | Rheumatoid arthritis | News

Study quantifies herpes zoster risk with JAK inhibitors, other DMARDs

A comparison of different treatments for rheumatoid arthritis suggests that Janus kinase inhibitors are associated with the highest risk for herpes zoster, while some biologic DMARDs may also be linked to an increased risk.

03-02-2021 | Rheumatoid arthritis | News

Potential drug–drug interactions with JAK inhibitors may be going unrecognized

In an analysis of a large US claims database, around 10% of patients with rheumatoid arthritis were prescribed a drug with the potential to interact with JAK inhibitors.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Image Credits